Dr Reddy's Takeda Qdenga India Distribution Deal
Analysis based on 30 articles · First reported Sep 18, 2026 · Last updated Sep 18, 2026
The deal gives Dr. Reddy's an exclusive commercial foothold in India's first approved dengue vaccine, potentially adding a new high-margin private-market revenue stream from 2027 and reinforcing its vaccine franchise. For Takeda, it secures a large-market distribution partner for QDENGA while retaining public-market and brand rights, modestly positive for both companies' growth outlooks though near-term earnings impact is limited given the 2027 launch timeline.
Abbott Laboratories and Takeda Pharmaceutical Company announced on September 18, 2026 an exclusive distribution agreement under which Dr. Reddy's will promote and distribute Takeda's dengue vaccine QDENGA across India's private market for pediatric and adult vaccination. The vaccine, India's first approved dengue vaccine, received marketing authorisation from the India — Central Drugs Standard Control Organisation in July 2026 for individuals aged 4-60 years. Subject to completion of applicable processes with local authorities, QDENGA is anticipated to become available in India in the first half of 2027. Under the deal, Dr. Reddy's is the exclusive partner for promotion and distribution in the private market, leveraging its position as India's second-largest vaccine player, its healthcare professional network and nationwide distribution infrastructure. Takeda retains rights to promote and distribute QDENGA in India's public market, as well as legal ownership and overall medical and brand oversight. QDENGA is a live-attenuated tetravalent vaccine providing broad immune coverage across all four dengue serotypes, administered as a two-dose regimen three months apart. It has been approved in more than 40 countries and received prequalification from the World Health Organization, with over 24 million doses distributed globally according to India's Union Health Ministry. Dengue remains a major public health challenge in India, with reported cases increasing 11-fold over the past two decades and all four serotypes co-circulating, according to a study by the India — Indian Council of Medical Research's Virus Research and Diagnostic Laboratory network.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard